1549TiP DeLLphi-303: Phase Ib first-line combination study of tarlatamab, a DLL3-targeting half-life extended bispecific T-cell engager (HLE BiTE®), with carboplatin, etoposide, and PD-L1 inhibition in extensive stage small cell lung cancer (ES-SCLC)
S.M. Gadgeel, J. Al-Mondhiry(University of Southern California), M-J. Ahn(Samsung Medical Center), S-W. Kim(Ulsan College), L. Paz-Ares(Hospital Universitario 12 De Octubre), H. Prenen(Antwerp University Hospital), M. Boyer(Chris O’Brien Lifehouse), J.G. Bustamante Alvarez(West Virginia University), B. Solomon(Avera McKennan Hospital & University Health Center), S. Huang(Amgen (United States)), M. Minocha(Amgen (United States)), M. Kistler(Amgen (United States)), N. Hashemi Sadraei(Amgen (United States))
Cited by 5
Abstract
Related Papers
No related papers found
Powered by citation graph analysis